JonesResearch analyst Sean Kim initiated coverage of Ovid Therapeutics (OVID) with a Buy rating and $6 price target. Ovid is a clinical-stage biopharmaceutical company with its lead asset soticlestat in development by partner Takeda (TAK) for the treatment of developmental and epileptic encephalopathy syndromes such as Dravet syndrome and Lennox-Gastaut syndrome, the analyst tells investors in a research note. If approved, the analyst anticipates “highly lucrative” revenue opportunities for Ovid, including an aggregate amount of up to $660M in milestone payments.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on OVID:
- Is OVID a Buy, Before Earnings?
- Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
- Ovid Therapeutics announces collaboration agreement with Graviton Bioscience
- Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
- Ovid reports Takeda presented interim soticlestat data at AAN meeting